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Background: As IL-12 and IL-18 have important immunostimulatory role the aim of this study was to investigate
their in vitro effects on functional and receptor characteristics of NK cells and their subsets in healthy controls (HC)
and metastatic melanoma patients (MM).
Methods: Peripheral blood mononuclear cells (PBMC) of HC and MM were stimulated with culture medium
alone, medium supplemented with IL-12 (10 ng/ml), IL-18 (100 ng/ml) and their combination. NK cell activity was
determined using radioactive cytotoxicity assay, while perforin, CD107a and pSTAT-4 expression, IFN-γ production
and the expression of NKG2D, DNAM-1, CD161, CD158a/b, CD25, IL-12R beta 1/2 receptors on CD3−CD56+ NK
cells and their CD3−CD56dim+ and CD3−CD56bright+ subsets were analyzed by flow cytometry. Cytokine induced
level of DAP10 in PBMC was analyzed by reverse transcription polymerase chain reaction.
Results: IL-12 alone or in combination with IL-18 significantly induced NK cell activity and CD107a degranulation
marker expression in MM and HC, while IL-18 alone did not have any effect in patients. The combination of IL-12
and IL-18 significantly increased mean fluorescence intensity (MFI) of IFN-γ in all NK cell subsets in HC and only in
the bright subset in MM. MM that belong to M1c group with metastasis in liver and increased LDH serum values
had significantly lower increase in NK cell cytotoxicity after combined IL-12 and IL-18 treatment compared to the
patients in M1a and M1b categories. These results could be explained by decreased IL-12R expression and lower
increase in pSTAT-4 and perforin expression in NK cells of M1c patients after IL-12 and combined IL-12 and IL-18
treatment. IL-18 alone significantly decreased NKG2D receptor expression and level of DAP10 signaling molecule
in MM, while combined IL-12 and IL-18 increased the expression of CD25 on all NK cell subsets in HC and MM.
Additionally, MM that belong to M1a + M1b group had significantly higher increase in CD25 receptor expression
compared to the patients in M1c group.
Conclusions: The novel data obtained in this study support the use of IL-12 and IL-18 in combination for developing
new therapeutic strategies for metastatic melanoma especially for patients with better survival rate and prognosis.
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Human natural killer (NK) cells are important compo-
nents of the innate immune system that are able to lyse
transformed cells without prior sensitization. They exert
cytotoxic function by releasing perforin and granzymes
from their granules and have an immunoregulatory role
by producing many cytokines especially IFN-γ that regu-
late adaptive T-cell-mediated anti-tumor response [1].
CD107a, the main membrane molecule of cytolytic gran-
ules of NK cells is strongly upregulated on the surface of
these cells after their contact with tumor and its expres-
sion is associated with perforin release. In this sense,
CD107a has been described as a marker of NK cell de-
granulation and cytotoxicity [2].
The balance between NK cell activating and inhibitory
signals mediated by various receptors regulates NK cell ef-
fector functions [3]. The most important activating NK re-
ceptors are NKG2D, natural cytotoxicity receptors (NCR)
and DNAX accessory molecule-1 (DNAM-1). NKG2D,
as the most prominent activating c-lectin-like receptor,
mediates immune responses that are beneficial in the
surveillance against cancer [4]. This receptor upon bind-
ing to stress induced ligands constitutively expressed on
transformed cells such as MHC-class-I-related molecules,
MICA/MICB and ULBP1-4, induces NK cell cytotoxicity
in association with DAP10 adaptor molecule [5]. DNAM-
1 is a co-receptor expressed by virtually all NK cells and
its stimulation by interaction with the members of the
nectin family, PVR (CD155) and Nectin-2 (CD112), on
tumor cells leads to NK cell activation and target cell lysis
[6]. Another common NK cell receptor, CD161, one of the
earliest markers in NK cell development, is primarily de-
scribed as an activating receptor [7].
Contrary to this, killer immunoglobulin-like receptors
(KIRs) that belong to the immunoglobulin superfamily
are responsible for the inhibition of NK cell-mediated
lysis of normal cells that express MHC-I molecules. In
this sense, according to the “missing-self” hypothesis, the
activation of NK cells occurs in contact with malignantly
transformed cells that have lost MHC-I molecules, and
therefore become susceptible to lysis [8]. According to the
length of their cytoplasmatic tail KIR are classified into
long (e.g., KIR2DL and KIR3DL), inhibitory, and short
(e.g., KIR2DS and KIR3DS) stimulating receptors, al-
though inhibitory KIRs are dominant [9].
In humans, CD3−CD56+ NK cells can be subdivided in
two functionally and phenotipically different subsets based
on CD56 receptor expression. CD3−CD56dim+ subset, that
aside from high expression of inhibitory KIR receptors
and CD16 activating receptor, also expresses abundant
perforin and granzymes in their granules and is involved
in NK cell cytotoxicity. The other CD3−CD56bright+ sub-
set, with low expression of CD16 and low to absent ex-
pression of KIR receptors has a regulatory function,owing to its abundant cytokine production and weak
cytotoxicity [10].
As it is known that melanoma patients with advanced
disease have impairments in their immune response, in-
cluding decreased NK cell activity [11], and that melan-
oma is an immunogenic tumor resistant to chemotherapy
and irradiation, immunomodulating agents such as cyto-
kines have been included in its treatment [12]. In this
sense, IFN-α and IL-2 are administrated in the immuno-
therapy of melanoma for several decades [12,13]. On the
other hand, considering that their therapeutic effects are
limited, many other cytokines, such as IL-12 and IL-18
have been investigated in this disease [14,15].
Interleukin-12 (IL-12) is a cytokine that is produced
primarily by antigen-presenting cells and by enhancing
NK and T cell cytotoxicity, inducing IFN-γ production
from these cells and favoriting Th1 differentiation plays
an essential role in the interaction between the innate
and adaptive immunity [16]. Interleukin-18 (IL-18) is an
immunoregulatory and proinflammatory cytokine that
belong to the IL-1 family. It shows numerous effects not
only on NK cells, but also on monocytes, dendritic cells
(DCs), T cells. IL-18 acts synergistically with IL-12 to pro-
mote cytotoxicity and IFN-γ production from NK and T
cells [17] and also it is involved in NK cell priming [18]
and the interaction between DCs and NK cells [19].
As IL-12 and IL-18 have an important role in improving
anti-tumor immune response they could have a great po-
tential in cancer immunotherapy. We, therefore, consider
that it is of interest to assess in vitro effects of IL-12, IL-18
and their combination on NK cell effector functions, cyto-
toxicity and IFN-γ production, as well as on the expres-
sion of numerous receptors on NK cells and their dim and




Peripheral venous blood was obtained from 36 MM pa-
tients (stage IV according to 7th modified AJCC/UICC sta-
ging system) [20] and 26 HC, age and gender matched,
with no evidence of any disease or infection. Blood was
drawn at the time of diagnosis prior to chemotherapy. Be-
fore inclusion in the study, informed consent was signed
by each patient and healthy volunteer and approved by
the Ethical committee of Institute of Oncology and Radi-
ology of Serbia. The characteristics of MM patients and
HC enrolled in this study are listed in Table 1. Further-
more, MM patients are divided in 2 groups based on the
localization of distant metastases according to AJCC/
UICC staging system. Patients that have metastases in dis-
tant skin, the subcutaneous layer or in distant lymph
nodes and normal values of serum lactate dehydrogenase
(LDH) (<460 IU/l) (M1a) and patients with metastases in
Table 1 The characteristics of metastatic melanoma (MM)
patients and healthy controls (HC)
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the patients with metastases in vital organs other than the
lungs with normal serum LDH level or the patients that
have any distant metastasis with elevated LDH (>460 IU/l)
are included in M1c group.
Peripheral blood mononuclear cell (PBMC) isolation
PBMC were isolated from heparinized blood obtained
from HC and MM patients using Lymphoprep (Nypacon,
Oslo, Norway) density gradient, centrifuged at 500 g for
40 min, and washed three times in RPMI 1640 culture
medium (CM), (Sigma, St. Louis, USA) supplemented
with 10% fetal calf serum (FCS) (Sigma). After washing
PBMC were immediately used for functional, phenotypic
and molecular analysis.
In vitro treatment of PBMC with various cytokines
PBMC isolated from HC and MM patients were cultivated
in CM alone, CM supplemented with IL-12 (10 ng/ml)(Becton Dickinson, San Jose, USA), IL-18 (100 ng/ml)
(R&D, Minneapolis, USA) and IL-12 and IL-18 in combin-
ation, in six well plates at 37°C and 5% CO2 in humid
atmosphere.
NK cell assay
PBMC was determined using standard cytotoxicity assay
[21]. One hundred microlitres of PBMC, as effector
cells, at concentration of 4.0 × 106/ml of CM and two
1:1 dilutions were mixed with 100 μl of the erythromye-
loid cell line K562, as target cells, at concentration of
0.05 × 106/ml, prelabeled with radioactive 51Chromium
(Na2CrO4, As = 3.7 MBq, Amersham, UK), to form trip-
licates of three effector cell (E) to target cell (T) ratios
(E:T), 80:1, 40:1 and 20:1. The assay was performed in
96 round bottom microwell plates (Sigma), which were
incubated in an incubator at 37°C, in a humidified atmos-
phere containing 5% CO2. Plates were, then centrifuged
for 3 min at 200 g and the supernatant from each well was
used for determination of the amount of released 51Chro-
mium from the lysed K562 cells in a gamma counter
(Berthold, Oak Ridge, USA) and expressed in counts per
minute (cpm). The mean percent cytotoxicity was calcu-
lated using the following formula:
cpm experimental releaseð Þ‐cpm spontaneous releaseð Þ
cpm maximal releaseð Þ ‐ cpm spontaneous releaseð Þ X 100
Maximal release was obtained by incubation of target
K562 tumor cells at the same concentration in the
presence of 5% TritonX-100, and spontaneous release
was obtained by incubation of K562 cells in culture
medium, alone.
Flow cytometric analysis
Surface immuno-phenotype of 18 h in vitro treated PBMC
subsets were identified using the following combinations of
directly labeled monoclonal antibodies (mAbs): CD3PerCP
(clone SK7)/CD56FITC (clone NCAM 16.2)/IL-12Rbe-
ta1PE (clone 2.4E6), CD3PerCP/CD56FITC/IL-12Rbeta2PE
(clone 2B6/12 beta 2), CD3PerCP/CD56FITC/DNAM-
1PE (clone DX11), CD3PerCP/CD56FITC/CD161PE (clone
DX12), CD3PerCP/CD56FITC/CD158bPE (clone CH-L),
CD3PerCP/CD56PE (clone NCAM 16.2)/CD158aFITC
(clone HP-3E4), CD3PerCP/CD56FITC/CD25PE (clone
M-A251) (Becton Dickinson) and CD3PerCP/CD56FITC/
NKG2DPE (clone 149810) (R&D). The samples were
prepared as previously described [22]. Briefly, 1.0 × 105
PBMC in 100 μl RPMI 1640 supplemented with 10%
FCS were incubated for 30 min at 4°C with 20 μl of ap-
propriate mAbs combination, washed twice with ice-
cold phosphate-buffered saline (PBS) and fixed with 1%
paraformaldehyde prior to flow cytometry analysis. Sur-
face marker expression was quantified on FACSCalibur
flow cytometer (Becton Dickinson). A total of 50 000
Mirjačić Martinović et al. Journal of Translational Medicine  (2015) 13:120 Page 4 of 14gated events, verified as PBL according to their physical
characteristics (FSC and SSC), were collected per sam-
ple and analyzed using CellQUEST software. Exclusion
of non-specific fluorescence was based on matched
IgG1 isotype mAb combinations conjugated with FITC
(clone X39), PE (clone X40) and PerCP (clone SK7)
(Becton Dickinson). NK cells were defined and gated
within the lymphocyte gate according to their expression
of CD3 and CD56 (CD3−CD56+). In order to define the
two NK cell subsets of CD56 low, i.e., CD3−CD56dim+ or
CD56 high, i.e., CD3−CD56bright+ subsets, CD3−CD56+
NK cells were divided based on the density of CD56 anti-
gen defined by mean fluorescence intensity (MFI). MFI re-
fers to the fluorescence intensity of each event in average
and represents the expression quantity of the parameter
on each event. NK cell receptors, IL-12R beta 1, IL-12R
beta 2, NKG2D, DNAM-1, CD161, CD158a, CD158b
and CD25 were expressed as the percentage or MFI on
gated CD3−CD56+ NK cells and their CD3−CD56dim+
and CD3−CD56bright+ NK cell subsets.
CD 107 degranulation assay
100 μl of 18 h in vitro stimulated PBMC (3x106cells/ml)
from HC and MM patients were cultured with 100 μl of
washed K562 (2x106/ml) for 4 hours at 37°C in a humidi-
fied atmosphere in CO2 incubator. Monensin (Sigma) at
the final concentration of 2 μl/ml was added after 1 hour of
incubation. Cells were afterwards stained with CD56FITC,
CD107aPE (clone H4A3) and CD3PerCP mAbs (Becton
Dickinson). The percentage and MFI of CD107a was es-
timated on gated CD3−CD56+ NK cells, as well as on
CD3−CD56dim+ and CD3−CD56bright+ NK subsets by flow
cytometry. Spontaneous CD107a expression was deter-
mined in absence of K562 cells.
Intracellular IFN-gamma, phosphorylated STAT-4 and
perforin analyses
For measurement of phosphorylated pSTAT-4 20 min
and for measurement of IFN-γ and perforin 18 h in vitro
stimulated PBMC (1x106/ml) from HC and MM patients
were analyzed. Three hours before IFN-γ analysis, brefel-
din A was added at concentration of 10 μg/ml. The
cells were then stained with mAbs against cell surface
molecules: CD3PerCP, CD56PE (for IFN-γ analysis) and
CD56FITC (for pSTAT-4 and perforin analyses) (Becton
Dickinson), followed by fixing and permeabilizing with the
Permeabilizing Solution 2 (Perm 2) (Becton Dickinson)
accords to the manufacturer’s instructions. Then the cells
were incubated with anti-IFN-γFITC (clone 25723.11),
anti-pSTAT-4PE (clone 38/p-Stata4) (Becton Dickinson),
anti-Perforin RPE (clone deltaG9) (Invitrogen, Madison,
USA) or IgG1 isotype control (Becton Dickinson). Finally,
the cells were washed and analyzed by flow cytometry
directly after preparation. The percentages and MFI ofintracellular IFN-γ, pSTAT-4 and perforin were analyzed
in CD3−CD56+ NK cells and their CD3−CD56dim+ and
CD3−CD56bright+ subsets.
RT-PCR
For the analysis of DAP10 transcription level total RNA
was isolated from 18 h in vitro stimulated PBMC of HC
and MM patients using Trizol reagent (Invitrogen). One
microgram of total RNA was reverse transcribed by
random priming, incubated with 1 μl reverse transcript-
ase MuLV (Fermentas, St. Leon Rot, Germany), 10 mM
deoxynucleotide triphosphate mix (dNTP) (Fermentas),
RNAse inhibitor (Fermentas) and 2 μl 0.1 M dithiothrei-
tol (DTT) (Fermentas) for 1 h at 37°C and then 5 min at
99°C. Total cDNA was then amplified by PCR with spe-
cific primers: DAP-10 (350 bp) (up: 5′-CAG ACC CCA
GTC CAC CAT G-3′ and down: 5′-GTG CCA CCA
CAC ACC ATC-3′) and beta-Actin as housekeeping
gene (685 bp) (sense: 5′- TGG GTC AGA AGG ATT
CCT AT-3′ and antisense: 5′- AAG GAA GGC TGG
AAG AGT -3′). The optimal cycle conditions were 30 sec
at 94°C, 30 sec at 55°C, 30 sec at 72°C for 30 cycles. RT-
PCR results were analyzed on 1.5% agarose gels.
Quantification of blots and gels
Agarose gels were scanned by using gel-image system
(Kodak Image 1D Image 1 3.6.), in a grey scale mode at
169 mm pixel size and 1250–1650 (X–Y) pixel count,
using the autodensity feature on a scale ranging from 0
(clear) to 255 (opaque). The pixel density was deter-
mined and used to calculate the integrated density of a
selected band. Values of integrated density were reported
in volume units of pixel intensity per mm2.
Statistical analysis
Significance of differences for obtained results was done
by nonparametric Wilcoxon signed rank test and Mann–
Whitney exact test.
Results
The effect of investigated cytokines on NK cell cytotoxic
activity and IFN-γ production
We show that in both HC and MM patients NK cell
cytotoxic activity performed against standard sensitive
erythromyeloid K562 tumor target cell line after treat-
ment with 10 ng/ml of IL-12 alone or in combination
with IL-18 (100 ng/ml) is high significantly (p < 0.01,
Wilcoxon signed rank test) enhanced, while after treatment
with IL-18 alone is significantly (p < 0.05, Wilcoxon signed
rank test) augmented only in HC compared to the results
in CM. Contrary to this, in investigated MM patients IL-18
alone does not significantly (p > 0.05, Wilcoxon signed
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Figure 1 (See legend on next page.)
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Figure 1 The effect of cytokines on NK cell cytotoxic activity and IFN-γ production. a) In healthy controls (HC) and metastatic melanoma (MM)
patients high significant (**p < 0.01, Wilcoxon signed rank test) enhancement of NK cell cytotoxicity is obtained after 18 h in vitro treatment of
peripheral blood mononuclear cells (PBMC) with IL-12 alone (10 ng/ml), as well as with IL-12 in combination with IL-18 (100 ng/ml) that gives a
significant (*p < 0.05, Wilcoxon signed rank test) increase in HC only; b) In both HC and MM patients IL-12 alone or in combination with IL-18
significantly (*p < 0.05, Wilcoxon signed rank test) or high significantly (**p < 0.01, Wilcoxon signed rank test) increases the percentage and mean
fluorescence intensity (MFI) of CD107a degranulation marker on CD3−CD56+ NK cells and their CD3−CD56dim+ and CD3−CD56bright+ subsets, while
IL-18 alone significantly (*p < 0.05, Wilcoxon signed rank test) increases the expression of CD107a on NK cells and their subsets only in HC. Results
are obtained by Flow cytometry; c) In HC 18 h in vitro treatment of PBMC with combination of IL-12 and IL-18 high significantly (**p < 0.01,
Wilcoxon signed rank test) increases the percentage of IFN-γ only in the bright NK cell subset, while this combined cytokine treatment increases the MFI of
IFN-γ significantly (*p < 0.05, Wilcoxon signed rank test) in NK cells and their dim subset and high significantly (**p < 0.01, Wilcoxon signed rank test) in the
bright NK cell subset. In MM patients the combination of IL-12 and IL-18 significantly (*p < 0.05, Wilcoxon signed rank test) increases only the MFI of IFN-γ
in the bright subset. Results are obtained by Flow cytometry. All results are shown as mean ± SE for maximum 26 HC and 36 MM patients.
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patients IL-12 alone or in combination with IL-18 signifi-
cantly (p < 0.05, Wilcoxon signed rank test) or high signifi-
cantly (p < 0.01, Wilcoxon signed rank test) increases the
percentage or MFI of CD107a degranulation marker on
NK cells and both their dim and bright subsets. Contrary
to this, IL-18 alone, compared to the results in CM, signifi-
cantly (p < 0.05, Wilcoxon signed rank test) increases the
expression of CD107a only in HC (Figure 1b).
Furthermore, we analyze the production of intracellu-
lar IFN-γ in NK cells and their dim and bright subsets
in HC and MM patients after 18 h PBMC in vitro treat-
ments with IL-12, IL-18 and their combination. We
show that in HC, combined IL-12 and IL-18 treatment
high significantly (p < 0.01, Wilcoxon signed rank test)
increases the percentage of IFN-γ only in the bright NK
cell subset, while this cytokine treatment increases the
MFI of IFN-γ significantly (p < 0.05, Wilcoxon signed
rank test) in NK cells and the dim subset and high sig-
nificantly (p < 0.01, Wilcoxon signed rank test) in the
bright NK cell subset. In MM patients the combination
of IL-12 and IL-18 significantly (p < 0.05, Wilcoxon signed
rank test) increases only the MFI of IFN-γ in the bright
subset. Contrary to this, IL-12 or IL-18 alone does not
have any significant (p > 0.05, Wilcoxon signed rank test)
effect on IFN-γ production in NK cells and both their sub-
sets in HC, as well as in MM patients (Figure 1c).
The effect of investigated cytokines on the percentages
and absolute values of NK cells and their subsets
All investigated cytokines do not have any significant effect
(p > 0.05, Wilcoxon signed rank test) on the percentages,
as well as on the absolute values of NK cells and their dim
and bright subsets in HC and MM patients (Table 2).
The differences in cytokine-induced increase in NK cell
activity between M1a +M1b and M1c metastatic
melanoma patients
We show that patients in M1c group have significantly
(p < 0.05, Mann–Whitney exact test) lower enhancement
in NK cell cytotoxicity after in vitro treatment withcombination of IL-12 and IL-18 compared to the in-
crease in M1a +M1b group. IL-12 or IL-18 alone has
the similar effect on the induction of NK activity in both
groups of investigated MM patients (Figure 2a).
Furthermore, MM patients that have distant metastasis
in liver have significantly (p < 0.05, Mann–Whitney exact
test) or high significantly (p < 0.01, Mann–Whitney exact
test) lower enhancement in NK cell cytotoxicity after
in vitro treatment with IL-12 alone or in combination
with IL-18 compared to the increase in NK cell cytotox-
icity in MM patients with distant metastases in skin,
subcutaneous layer and lymph nodes. IL-18 alone has
the similar effect on the induction of NK activity in all
investigated groups of MM patients (Figure 2b).
MM patients with increased values of serum LDH
(LDH+) have significantly lower (p < 0.05, Mann–Whitney
exact test) upregulation of NK cell cytotoxicity after com-
bined IL-12 and IL-18 in vitro treatment compared to
patients with normal LDH values (LDH-) (Figure 2c).
The differences in IL-12 receptor expression and
cytokine-induced increase in pSTAT-4 and perforin
expression in NK cells between M1a +M1b and M1c
metastatic melanoma patients
Furthermore, we show that MM patients that belong to
M1c group have significantly (p < 0.05, Mann–Whitney
exact test) lower expression of both IL-12R, IL-12R beta
1 and IL-12R beta 2, on their NK cells compared to pa-
tients in M1a +M1b group (Figure 3a).
Analyzing the influence of the investigated cytokines on
pSTAT-4 signaling molecule expression in NK cells of
MM patients by Flow cytometry we show that 20 min
in vitro treatment with IL-12 increases this molecule MFI
significantly (p < 0.05, Mann–Whitney exact test) lower in
M1c group of patients compared to the increase in M1a +
M1b group. IL-18 alone or in combination with IL-12 has
the similar effect (p > 0.05, Wilcoxon signed rank test) on
the induction of pSTAT-4 expression in NK cells in both
groups of investigated MM patients (Figure 3b).
MFI of cytotoxic mediator, perforin, in NK cells is sig-
nificantly (p < 0.05, Mann–Whitney exact test) lower
Table 2 The percentages and absolute values of NK cell subsets after cytokine in vitro treatment
18 h in vitro treatment
Medium IL-12 IL-18 IL-12 + IL-18
Controls (n = 26) Percentage (%) CD3−CD56+ 13.76 ± 1.75# 14.58 ± 2.67 13.92 ± 2.66 12.47 ± 2.14
CD3−CD56dim+ 12.72 ± 1.76 13.39 ± 2.64 12.04 ± 2.26 11.53 ± 2.13
CD3−CD56bright+ 1.06 ± 0.11 1.18 ± 0.15 1.07 ± 0.20 0.90 ± 0.12
Apsolute values (/μl) CD3−CD56+ 261.53 ± 19.33 280.53 ± 29.33 255.28 ± 21.38 275.14 ± 23.33
CD3−CD56dim+ 250.87 ± 30.54 260.71 ± 32.55 249.39 ± 33.83 259.12 ± 35.22
CD3−CD56bright+ 19.63 ± 1.39 21.13 ± 0.19 18.87 ± 0.09 20.18 ± 1.01
Patients (n = 36) Percentage (%) CD3−CD56+ 16.61 ± 1.99 16.82 ± 2.11 17.70 ± 2.42 17.72 ± 2.31
CD3−CD56dim+ 15.56 ± 1.96 15.82 ± 2.10 16.63 ± 2.40 16.66 ± 2.29
CD3−CD56bright+ 1.05 ± 0.09 1.06 ± 0.08 1.07 ± 0.10 1.03 ± 0.12
Apsolute values (/μl) CD3−CD56+ 328.32 ± 21.33 319.83 ± 28.33 319.83 ± 25.13 338.51 ± 23.33
CD3−CD56dim+ 305.13 ± 20.96 300.75 ± 39.73 321.27 ± 27.23 325.17 ± 27.71
CD3−CD56bright+ 22.87 ± 0.19 25.34 ± 0.09 26.13 ± 0.33 20.01 ± 0.10
#Results are expressed as mean values ± SE. Absolute numbers were calculated by multiplying PBL number in the blood count with percentage for each subset
obtained by flow cytometry.
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or in combination with IL-18 in M1c group of patients
compared to M1a +M1b group. Contrary to this, IL-18
alone has the similar effect on the induction of perforin ex-
pression in NK cells in both groups of patients (p > 0.05,
Wilcoxon signed rank test) (Figure 3c).The effect of investigated cytokines on the activating
NKG2D, DNAM-1 and CD161 receptor expression on NK
cells and their subsets
Analyzing the modulation of NKG2D activating receptor
expression on CD3−CD56+ NK cells and their CD3−
CD56dim+ and CD3−CD56bright+ subsets with all investi-
gated cytokines we show that both percentage and MFI of
this receptor decrease significantly (p < 0.05, Wilcoxon
signed rank test) only in MM patients after 18 h in vitro
treatment with IL-18 on NK cells, as well as on their dim
subset. IL-12 alone or in combination with IL-18 does not
have any significant (p > 0.05, Wilcoxon signed rank test)
effect on the expression of this NK cell receptor on NK
cells, as well as on their subsets in HC and in MM
patients (Figure 4a).
Analyzing the modulation of DAP10, NKG2D adaptor
molecule, after 18 h cytokine treatments of PBMC in
HC, as well as in MM patients, we show that IL-18 alone
high significantly (p < 0.01, exact Wilcoxon signed rank
test) decreases mRNA level of this signaling molecule only
in MM patients (Figure 4b).
Analyzing the expression of DNAM-1 on NK cells and
their subsets, we show that, compared to treatment in
CM, the MFI of this receptor does not change significantly
(p > 0.05, Wilcoxon signed rank test) after 18 h in vitrotreatments with all investigated cytokines in HC, as well
as in MM patients (Figure 4c).
Obtained results from activating NK cell receptor,
CD161, show that in HC IL-12 alone or in combination
with IL-18 significantly (p < 0.05, Wilcoxon signed rank
test) or high significantly (p < 0.01, Wilcoxon signed
rank test) increases MFI of this receptor on NK cells
and their subsets. Contrary to this, in MM patients the in-
vestigated cytokines do not have any significant (p > 0.05,
Wilcoxon signed rank test) effect on CD161 expression on
NK cells and both dim and bright subsets (Figure 4d).The effect of investigated cytokines on the inhibitory KIR,
CD158a and CD158b, receptor expression on NK cells and
their subsets
Analyzing the expression of KIR receptor, CD158a, on
NK cells and their CD3−CD56dim+ and CD3−CD56bright+
subsets, we show that, compared to treatment in CM,
the percentage and MFI of this receptor do not change
significantly (p > 0.05, Wilcoxon signed rank test) after
18 h in vitro treatments with all investigated cytokines
in HC, as well as in MM patients (Figure 5a).
Furthermore, contrary to the percentage expression
of the other inhibitory KIR, CD158b, the MFI of this
receptor decreases significantly (p < 0.05, Wilcoxon
signed rank test) after 18 h in vitro treatment with
combined IL-12 and IL-18 on NK cells and their dim
subset in both HC and MM patients. IL-12 or IL-18
alone does not have any significant effect (p > 0.05,
Wilcoxon signed rank test) on CD158b expression on
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Figure 2 Cytokine-induced increase in NK cell activity in M1a +M1b
and M1c metastatic melanoma patients. a) Patients in M1c group have
significantly (*p < 0.05, Mann–Whitney exact test) lower enhancement in
NK cell cytotoxicity after in vitro treatment with combination of
IL-12 and IL-18 compared to the increase in M1a + M1b group;
b) Metastatic melanoma (MM) patients that have distant metastasis in
liver have significantly (*p < 0.05, Mann–Whitney exact test) or high
significantly (**p < 0.01, Mann–Whitney exact test) lower enhancement
in NK cell cytotoxicity after in vitro treatment with IL-12 alone or in
combination with IL-18 compared to the increase in NK cell cytotoxicity
in MM patients with metastases in skin, subcutaneous layer and
lymph nodes; c) MM patients with increased values of serum
lactate dehydrogenase (LDH+) have significantly lower (*p < 0.05,
Mann–Whitney exact test) upregulation of NK cell cytotoxicity
after combined IL-12 and IL-18 in vitro treatment compared to
patients with normal LDH values (LDH-). Results are expressed in
indexes calculated as the value of NK cell cytotoxicity after the
cytokine treatment of each MM patient devides with the value of
NK cell cytotoxicity after treatment in medium alone. All results
are shown as mean ± SE for maximum 36 MM patients.
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expression on NK cells and their subsets
Analyzing the expression of CD25 receptor we show that
both percentage and MFI of this receptor increase sig-
nificantly (p < 0.05, Wilcoxon signed rank test) on NK
cells and their dim and bright subsets in HC and MM
patients after 18 h in vitro treatment with IL-12 and
IL-18 in combination. IL-12 or IL-18 alone does not
have any significant (p > 0.05, Wilcoxon signed rank test)
effect on the expression of CD25 on NK cells and their
subsets in HC and in MM patients (Figure 6a).
We also show that HC and MM patients that belong
to M1a +M1b group have significantly (p < 0.05, Mann–
Whitney exact test) higher increase in CD25 receptor
expression on NK cells after in vitro treatment with com-
bined IL-12 and IL-18 compared to the increase in M1c
group (Figure 6b).
Discussion
In this study we demonstrate that NK cell cytotoxicity
and the expression of CD107a degranulation marker on
NK cells and both their subsets in HC are high signifi-
cantly augmented by the performed in vitro treatments
with IL-12, alone, or IL-12 and IL-18 in combination
that is in accord with the existing data [23-25]. It is well
known that these cytokines upon binding to their high
affinity receptors increase cytotoxicity of NK cells by indu-
cing perforin, granzymes, FasL, TRAIL gene transcription
either directly or indirectly by various STAT transcription
factors [26].
The role of IL-18 in regulating NK cell activity in healthy
individuals and especially in cancer patients is still very con-
troversial. The lower effect of this cytokine on the increase
of NK cell cytotoxicity in HC may be due to low, but de-
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Figure 3 IL-12 receptor and cytokine-induced increase in pSTAT-4
and perforin expression in M1a +M1b and M1c patients. a) Metastatic
melanoma (MM) patients in M1c group have significantly (*p < 0.05,
Mann–Whitney exact test) lower expression of IL-12R beta 1 and IL-12R
beta 2 on their NK cells compared to MM patients that belong to M1a +
M1b group. Results are obtained by Flow cytometry; b) 20 min in vitro
treatment with IL-12 increases pSTAT-4 expression in NK cells significantly
(*p < 0.05, Mann–Whitney exact test) lower in M1c group of patients
compared to the increase in M1a +M1b group; c) Mean fluorescence
intensity (MFI) of perforin in NK cells is significantly (*p < 0.05,
Mann–Whitney exact test) lower upregulated after in vitro treatment with
IL-12 alone or in combination with IL-18 in M1c group of patients
compared to M1a +M1b group. Results are obtained by Flow cytometry
and are expressed in indexes calculated as the value of pSTAT-4 or
perforin after the cytokine treatment of each MM patient devides
with the value of appropriate parameter after treatment in medium
alone. All results are shown as mean ± SE for 20 MM patients.
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when IL-18 is combined with IL-12 may also be associated
with this receptor as it has been shown that this receptor is
up-regulated by IL-12 or IL-15 stimulation [27]. Further-
more, we show for the first time that in MM patients IL-18
alone does not have any significant effect on NK cell cyto-
toxic function and CD107a expression on NK cells and
their subsets. It has been shown in new experimental mel-
anoma models that IL-18 may convert conventional Kit−
into Kit+ NK cells that have immunosuppressive role [28].
Furthermore, as we show in this study that no one of
investigated cytokine has the effect on the percentages,
as well as the absolute values of NK cells and their dim
and bright subsets in peripheral blood of HC and MM
patients, the shown enhancement in NK cell cytotoxic
function after in vitro cytokine treatment is not the con-
sequence of increased number of investigated NK cells.
As it is well known that IL-12 and IL-18 have pro-
nounced synergy in eliciting IFN-γ secretion from NK
cells [29], we show that contrary to significantly induced
MFI of IFN-γ in the entire population of cells, especially
in CD56bright+ subset in HC, in MM patients only the
bright subset produces significantly higher level of IFN-γ
after combined IL-12 and IL-18 stimulation. Further-
more, we show that the level of this induction in the
bright NK cell subset is significantly lower in MM pa-
tients compared to HC (data not shown). In this sense,
we suggest that the other main effector function of NK
cells, their immunoregulatory role, is suppressed in MM
patients.
It is well known that in MM patients, the sites of me-
tastases and serum levels of LDH are used to delineate
these patients into three M categories: M1a, M1b, and
M1c [20]. We show for the first time that the patients
belonging to M1c category especially those patients that
have distant metastasis in liver, as well as have increased
level of serum LDH have significantly lower increase in
NK cell cytotoxicity after in vitro treatment with com-
bined IL-12 and IL-18 compared to the patients in M1a
+M1b group that have metastases in distant skin, sub-
cutaneous layer, lymph nodes and normal LDH serum
values. These new data may suggest that contrary to
MM patients that belong to M1c category with liver me-
tastasis and elevated LDH, patients in M1a and M1b cat-
egories may be the target group for combined IL-12 and
IL-18 treatment.
Furthermore, we show for the first time that MM pa-
tients that belong to M1c category have decreased ex-
pression of both IL-12 receptor subunits, IL-12R beta 1
and IL-12R beta 2, on their NK cells. It is well known
that binding to IL-12R beta 1 and through IL-12R beta
2, IL-12 activates JAK-STAT signaling molecules, primar-
ily STAT-4, and regulating perforin level enhances NK
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Figure 4 The effect of cytokines on NKG2D, DNAM-1 and CD161 receptor expression on NK cell subsets. a) Percentage and mean fluorescence
intensity (MFI) of NKG2D receptor decrease significantly (*p < 0.05, Wilcoxon signed rank test) on CD3−CD56+ NK cells, as well as on CD3−CD56dim+
subset in metastatic melanoma (MM) patients after 18 h in vitro treatment with IL-18. Results are obtained by Flow cytometry; b) 18 h in vitro treatment
with IL-18 high significantly (**p < 0.01, exact Wilcoxon signed rank test) decreases DAP10 mRNA level in peripheral blood mononuclear cells (PBMC) of
MM patients. Results are obtained by RT-PCR with respect to β-actin level; c) MFI of DNAM-1 co-receptor does not change significantly (p > 0.05, Wilcoxon
signed rank test) on NK cells and both their subsets in healthy controls (HC) and MM patients after 18 h in vitro treatments of PBMC with
investigated cytokines. Results are obtained by Flow cytometry; d) In HC IL-12 alone or in combination with IL-18 significantly (*p < 0.05,
Wilcoxon signed rank test) or high significantly (**p < 0.01, Wilcoxon signed rank test) increases MFI of CD161 receptor on NK cells and
their subsets. Results are obtained by Flow cytometry. All results are expressed as mean ± SE for 19 HC and 23 MM patients.
Mirjačić Martinović et al. Journal of Translational Medicine  (2015) 13:120 Page 10 of 141 and IL-12R beta 2 expression on NK cells in M1c pa-
tients is in association with lower increase in pSTAT-4
and perforin expression in NK cells of these patientsafter IL-12 and combined IL-12 and IL-18 in vitro treat-
ment shown in this study. In this sense, these new data





























































































































































































































Figure 5 The effect of cytokines on CD158a and CD158b receptor expression on NK cell subsets. a) The percentage and mean fluorescence
intensity (MFI) of CD158a KIR receptor do not change significantly (p > 0.05, Wilcoxon signed rank test) on CD3−CD56+ NK cells and their CD3−CD56dim+
and CD3−CD56bright+ subsets in healthy controls (HC) and metastatic melanoma (MM) patients after 18 h in vitro treatments of peripheral
blood mononuclear cells (PBMC) with IL-12 or IL-18, alone, or with their combination; b) Contrary to the expression in percentage, MFI of
the other inhibitory KIR, CD158b, decreases significantly (*p < 0.05, Wilcoxon signed rank test) on NK cells and the dim subset in both healthy controls (HC)
and metastatic melanoma (MM) patients after 18 h in vitro treatment with IL-12 and IL-18 in combination. All results are obtained by Flow cytometry and
are expressed as mean ± SE for 18 HC and 27 MM patients.
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sponse to IL-12 or IL-12 and IL-18 in combination, the
potential immunotherapy of MM patients.
In this study we also give results regarding the influ-
ence of this newer generation of cytokines on NK cell
receptor expression.
We show for the first time that in MM patients IL-18
significantly decreases the expression of activating
NKG2D receptor on NK cells and their cytotoxic dim sub-
set. This result may explain inactiveness of IL-18 inincrease of NK cell cytotoxicity in MM patients obtained
in this study. Some clinical observations show that high
serum levels of IL-18 in cancer patients may be associated
with various NK cell defects [30,31], as well as that this
cytokine may have the role in melanoma metastases [32].
So downregulation of NKG2D after IL-18 in vitro treat-
ment shown in this study could facilitate escape of melan-
oma cells from NKG2D-mediated killing by NK cells.
Furthermore, we show for the first time that IL-18 de-






































































































































































Figure 6 The effect of cytokines on CD25 receptor expression on NK cell subsets. a) The percentage and mean fluorescence intensity (MFI) of
CD25 receptor increase significantly (*p < 0.05, Wilcoxon signed rank test) on CD3−CD56+NK cells and their CD3−CD56dim+ and CD3−CD56bright+
subsets in HC and MM patients after 18 h in vitro treatment with IL-12 and IL-18 in combination. Results are obtained by Flow cytometry; b) HC
and MM patients in M1a +M1b group have significantly (*p < 0.05, Mann–Whitney exact test) higher increase in CD25 receptor expression on NK
cells after in vitro treatment with combination of IL-12 and IL-18 compared to the increase in M1c group. Results are expressed in indexes calcu-
lated as the value of CD25 receptor expression after combined IL-12 and IL-18 treatment of each HC or MM patient devides with the value of this
receptor expression after treatment in medium alone.
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contributes not only to NK cells but also to CD8+ cyto-
toxic T lymphocytes (CTL)-mediated cytotoxicity via
NKG2D receptor [33], in our experimental data we did
not obtain the downregulation of NKG2D receptor on
CTL after IL-18 in vitro PBMC treatment (data not
shown). Therefore, decreased level of DAP10 in MM
patients shown in this study could be associated with
decreased NKG2D expression on NK cells and their
dim subset in MM patients after IL-18 in vitro treat-
ment. So far, there are no data regarding the effect of
IL-12 and IL-18 on DAP10 level in NK cells and their
subsets in MM patients.
As we show in this study that IL-12, IL-18 and their
combination do not have any significant in vitro effect
on DNAM-1 expression on NK cells and their subsets
in HC, as well as in MM patients it is possible that
DNAM-1 receptor expression on NK cells is not onlythe cytokine but also experimental conditions-dependent
that is in accord with a few data in literature [34,35].
Furthermore, according to this study, IL-12 alone or in
combination with IL-18 significantly increases CD161
expression on NK cells and their subsets only in HC. It
is well known that the expression of CD161 is upregu-
lated specifically by IL-12 [36]. The new results obtained
in this study show that IL-12-induced CD161 activating
receptor upregulation on NK cells and their subsets in
HC, could be associated with this cytokine-increased NK
cell cytotoxicity.
The data regarding the effect of cytokines on KIR ex-
pression in cancer patients are very rare [37]. It is now
known that KIR downregulation could indicate a state of
NK cell hyporesponsiveness [38]. In this sense, our new
results regarding IL-12 and IL-18 in vitro effect on KIR
expression could indicate that in HC and MM patients
combined IL-12 and IL-18 treatment by decreasing
Mirjačić Martinović et al. Journal of Translational Medicine  (2015) 13:120 Page 13 of 14CD158b receptor MFI on NK cells and cytotoxic dim
subset regulates NK cell responsiveness and effector
function. On the other hand, the observations obtained
in this study may suggest the existence of cytokine-
specific mechanisms of NK cell receptor expression
regulation that is important in the maintenance of NK
cell cytolytic machinery.
In this study we show for the first time that only com-
bined IL-12 and IL-18 treatment significantly increases
CD25, α chain of IL-2 receptor, on NK cells and both
their subsets in HC, as well as in MM patients resulting
in a constitution of functional high-affinity IL-2R (IL-
2Rαβγ). However, we show that HC and MM patients
that belong to M1a +M1b group have significantly
higher increase in CD25 receptor expression after
in vitro combined IL-12 and IL-18 treatment compared
to the patients in M1c group. Recent data regarding
mice in vivo and human healthy in vitro models show
that IL-12, IL-15 and IL-18 preactivated NK cells express
high level of CD25, proliferate rapidly and have en-
hanced effector functions especially IFN-γ production
after stimulation with IL-2 [39]. Furthermore, these NK
cells and their subsets are long-lived and might have
memory-like properties [40,41]. Our new results suggest
that adoptive transfer of IL-12 and IL-18 preactivated
NK cells simultaneously treated with exogenous low
dose of IL-2 may have an important place in immuno-
therapy of metastatic melanoma patients especially those
patients belonging to M1a and M1b categories that have
better survival outcome and prognosis.
Conclusions
In this study we give insight into novel activation mech-
anisms of NK cells in HC and MM patients that underlie
the effects of cytokines, IL-12, IL-18 and their combin-
ation. There are rare data about the role of these cyto-
kines in the regulation of NK cell effector functions and
the expression of various activating and inhibitory recep-
tors on these cells and their dim and bright subsets in
MM patients. Based on our new results, we suggest that
in vitro treatment with IL-12 and IL-18, in combination,
compared to IL-12 and IL-18 treatment, alone, have a
prominent effect on NK cell cytotoxicity, IFN-γ produc-
tion and the expression of CD25 receptor on NK cells in
MM patients and especially in HC. Furthermore, MM
patients that belong to M1c group especially those pa-
tients that have metastasis in liver and increased LDH
serum values have significantly lower increase in NK cell
cytotoxicity after in vitro treatment with IL-12 and IL-18
in combination compared to the patients that belong to
M1a +M1b group. These results could be explained by
decreased IL-12R beta 1 and IL-12R beta 2 expression
on NK cells in M1c patients that is in association with
lower increase in pSTAT-4 and perforin expression inNK cells of these patients after IL-12 and combined IL-
12 and IL-18 in vitro treatment found for the first time
in this study. So therapeutic strategies based on the
adoptive transfer of IL-12 and IL-18 in combination pre-
activated NK cells might have an important place in im-
munotherapy of metastatic melanoma patients with
better survival outcome and prognosis.
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